Sanofi steps up with a $645M deal to part­ner with As­traZeneca on a late-stage RSV an­ti­body

Point­ing di­rect­ly at a piv­otal Phase III pro­gram, As­traZeneca has de­cid­ed to part­ner with Sanofi on an ex­per­i­men­tal an­ti­body for RSV.

The French phar­ma gi­ant is pay­ing €120 mil­lion up­front and up to €495 mil­lion more in de­vel­op­ment and sales mile­stones to buy in­to the pro­gram. The two Big Phar­mas will now split R&D costs for ME­DI8897, with As­traZeneca in charge of man­u­fac­tur­ing and Sanofi Pas­teur tak­ing con­trol of the com­mer­cial­iza­tion work — pro­vid­ed it goes through to an ap­proval.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER